Simon E. Thurnheer , Martin W. Huellner , Deniz Kasikci , Grégoire B. Morand
{"title":"Early-stage oral cavity cancer (T1N0) with lymphatic drainage to the retropharyngeal lymph node: A therapeutic challenge","authors":"Simon E. Thurnheer , Martin W. Huellner , Deniz Kasikci , Grégoire B. Morand","doi":"10.1016/j.oor.2025.100713","DOIUrl":"10.1016/j.oor.2025.100713","url":null,"abstract":"<div><div>We report a case of a 54-year-old patient diagnosed with T1N0M0 oral squamous cell cancer located at the right maxillary tuberosity. The treatment plan included wide local excision with partial maxillectomy and sentinel lymph node biopsy. Preoperative single photon emission computed tomography/computed tomography (SPECT/CT) revealed lymphatic drainage to a single ipsilateral retropharyngeal lymph node (Rouvière's node/level VIIa). Due to the poor surgical accessibility of this lymph node, the decision was made to proceed with the tumor resection without sentinel lymph node excision, focusing instead on assessing the tumor's depth of infiltration to estimate the risk of metastasis. Histopathological analysis of the specimen confirmed clear margins with 2mm depth of infiltration. Consequently, the patient was placed under observation. This case represents the first reported instance of sentinel lymph node drainage to Rouvière's node in early oral squamous cell carcinoma, presenting a unique diagnostic and therapeutic challenge.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100713"},"PeriodicalIF":0.0,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143145795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Oligometastatic squamous cell carcinoma treated with and without involved site radiation","authors":"Allen M. Chen","doi":"10.1016/j.oor.2024.100707","DOIUrl":"10.1016/j.oor.2024.100707","url":null,"abstract":"<div><h3>Purpose</h3><div>Comprising a heterogenous population, the optimal management of oligometastatic head and neck cancer is uncertain. We sought to report outcomes among patients treated with and without stereotactic body radiotherapy (SBRT) to local sites of disease.</div></div><div><h3>Methods and materials</h3><div>A review of institutional registries identified 49 patients with metastatic squamous cell carcinoma of the head and neck limited to 5 sites of disease or less. Patients with intact disease at primary local-regional sites; those treated by palliative radiation; and those who had previously received first-line systemic therapy were excluded.</div></div><div><h3>Results</h3><div>A total of 20 patients met eligibility criteria. Treatment included systemic therapy alone (10 patients) and systemic therapy with SBRT (10 patients). The median progression-free survival was 11 months and 6 months, respectively (p = 0.09). The 2-year overall survival was 29 % and 15 % for patients treated by SBRT and systemic therapy compared to systemic therapy alone, respectively (p = 0.21). There were no differences in the development of grade 3+ toxicity between the 2 groups, with the incidence of grade 3+ toxicity being 20 % and 30 % for patients treated with and without SBRT, respectively (p = 0.61).</div></div><div><h3>Conclusion</h3><div>Local SBRT was associated with trends in improved progression-free survival among patients with oligometastatic head and neck cancer. Prospective studies with larger datasets are warranted to further evaluate the role of this modality in this setting.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100707"},"PeriodicalIF":0.0,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143146694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"In response to Fiorillo: Agreeing on the need to rethink the demonization of AI writing tools such as ChatGPT","authors":"Dag Øivind Madsen, Shahab Saquib Sohail","doi":"10.1016/j.oor.2024.100712","DOIUrl":"10.1016/j.oor.2024.100712","url":null,"abstract":"","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100712"},"PeriodicalIF":0.0,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143145783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Insulin receptor substrate 1 (IRS 1) serum levels in patients with Oral Squamous Cell Carcinoma","authors":"Deeksheetha Prabhuvenkatesh , Karthikeyan Ramalingam , Pratibha Ramani , Selvaraj Jayaram","doi":"10.1016/j.oor.2024.100708","DOIUrl":"10.1016/j.oor.2024.100708","url":null,"abstract":"<div><h3>Aim</h3><div>To assess the expression of IRS 1 values in Oral Squamous Cell Carcinoma (OSCC) patients and its association with histological grading, tumor staging, and habits.</div></div><div><h3>Objective</h3><div>To assess the expression of IRS1 in patients with oral squamous cell carcinoma. To correlate IRS1 values with histological grading, tumor staging, habits, and overall survival in OSCC patients.</div></div><div><h3>Materials and methods</h3><div>IRS 1 values were assessed in N = 106 patients. IRS 1 values in 53 OSCC patients at preoperative and postoperative 3 months and were compared with 53 healthy controls using the sandwich ELISA method. The IRS 1 values were associated with clinicohistopathological factors. Statistical analysis was carried out using SPSS version 23.0 by IBM. One-way ANOVA and paired student t-tests were carried out and any p-value less than 0.05 was considered significant.</div></div><div><h3>Results</h3><div>The mean preoperative IRS 1 value in OSCC patients was 0.071 <em>±</em> 0.013, (p-value <0.001) and the mean postoperative 3 months IRS 1 value was 0.103 <em>±</em> 0.037 (p-value = 0.025). The mean IRS 1 value of healthy controls was 0.134 <em>±</em> 0.111 (p-value <0.001). The mean values in preoperative OSCC patients were underexpressed, compared to healthy controls and postoperative OSCC patients.</div></div><div><h3>Conclusion</h3><div>IRS1 expression was associated with various clinicopathological factors such as habit status, pathological tumor staging, and tumor grading. It was also found that underexpression of IRS1 was associated with poor prognosis of OSCC patients.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100708"},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143145794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Response to “The application of ChatGPT in the peer-reviewing process”","authors":"Dag Øivind Madsen, Shahab Saquib Sohail","doi":"10.1016/j.oor.2024.100709","DOIUrl":"10.1016/j.oor.2024.100709","url":null,"abstract":"","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100709"},"PeriodicalIF":0.0,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143145792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Integrating machine learning to customize chemotherapy for oral cancer patients","authors":"Saraswati Patel , Divya Yadav , Dheeraj Kumar","doi":"10.1016/j.oor.2024.100711","DOIUrl":"10.1016/j.oor.2024.100711","url":null,"abstract":"<div><div>Oral cancer, particularly oral squamous cell carcinoma (OSCC), poses a significant global health burden, with over 350,000 new cases annually. Despite chemotherapy being critical for advanced-stage treatment, its lack of personalization often results in inconsistent responses, severe side effects, and limited efficacy. Current methodologies, such as rule-based systems and traditional statistical models, fail to account for the complex, nonlinear interactions between patient-specific factors and drug responses, underscoring the need for advanced solutions. This paper introduces a machine learning (ML)-driven framework to optimize chemotherapy regimens for oral cancer patients. By leveraging multi-modal datasets, including genomic profiles, clinical histories, tumor burden indices, and drug toxicity metrics, the proposed model achieves remarkable results. Utilizing an ensemble of random forests and neural networks, the framework achieves an accuracy of 92 %, outperforming existing ML methods (85 %) and traditional approaches (78 %). Additionally, it demonstrates a 25 % reduction in chemotherapy-induced toxicity and a 20 % decrease in treatment costs. Key innovations include a novel efficacy-toxicity trade-off metric and adaptability through reinforcement learning for real-time regimen refinement. To address data privacy concerns, the framework incorporates federated learning, ensuring scalability across diverse healthcare systems. Preliminary results highlight a 15–20 % improvement in treatment efficacy and a 10 % reduction in adverse effects compared to existing methods. This interdisciplinary approach bridges the gap between oncology and ML, offering a robust foundation for personalized medicine. By tailoring chemotherapy regimens, this framework aims to improve survival rates, minimize treatment-related complications, and enhance the quality of life for oral cancer patients globally.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100711"},"PeriodicalIF":0.0,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143145793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gregory T. Wolf , Emily Bellile , Celine Mauquoi , Ariane Nguyen , Maureen Sartor , Siyu Liu , Laura Rozek , Jonathan B. McHugh
{"title":"Neoadjuvant cytokine (IRX-2) immunotherapy for resectable oral cavity carcinoma: Final results of the INSPIRE trial","authors":"Gregory T. Wolf , Emily Bellile , Celine Mauquoi , Ariane Nguyen , Maureen Sartor , Siyu Liu , Laura Rozek , Jonathan B. McHugh","doi":"10.1016/j.oor.2024.100706","DOIUrl":"10.1016/j.oor.2024.100706","url":null,"abstract":"<div><div>Oral cavity squamous carcinoma is characterized by alterations in cell mediated tumor immunity including a lack of immune reactive tumor infiltrating lymphocytes (TILs). To determine if a novel neoadjuvant injection of a multi-cytokine biologic (IRX-2) can restore immune reactivity and enhance patient survival, a randomized Phase 2 clinical trial was conducted in patients with Stage II-IV OSCC undergoing surgical resection (NCT 02609386).</div><div>The intention-to-treat (ITT) enrollment included 105 previously untreated patients, however 9 were excluded from the secondary endpoint analysis group for wrong histology, no treatment or patient refusal. A total of 96 patients comprised the final analytic group and were randomized (2:1) to receive the IRX-2 regimen (Regimen 1) compared to the identical regimen without IRX-2 cytokines (Regimen 2). Toxicity, tumor and immune responses, event-free (EFS) and overall (OS) survival were determined. Kaplan-Meier estimates for OS and EFS and inferential comparisons and asymptotoic log-rank testing between the two treatments were determined.</div><div>In prior preliminary analysis, significant increases in TILs and DMBT1 gene expression were noted for the IRX arm. No significant correlations of immunologic or tumor responses with survival outcomes were found. For the ITT population (n = 105) there were no significant differences in OS by treatment arm. OS [95 % CI] at 48 mo. was 70.4 [57.6, 80.0] vs 66.3 [47.5, 79.8] mos. (Regimen 1 vs Regimen 2, respectively).</div></div><div><h3>Conclusions</h3><div>Significant differences in survival were not seen, however, the trial demonstrated the feasibility of the neoadjuvant immunotherapy and differing immune modulation in each treatment arm. No correlations of immune biomarkers or tumor size changes with survival outcomes were identified.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100706"},"PeriodicalIF":0.0,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143145772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The impact of ctDNA on metastatic cancer management: Current trends and future directions","authors":"Omveer Singh , Usha Kumari Sah , Jay Chandra , Saraswati Patel","doi":"10.1016/j.oor.2024.100705","DOIUrl":"10.1016/j.oor.2024.100705","url":null,"abstract":"<div><div>Circulating tumor DNA (ctDNA) has emerged as a transformative tool in metastatic cancer management, offering a non-invasive approach for diagnosis, monitoring, and personalized treatment. This report examines recent advancements in ctDNA technology and its impact on oncology. ctDNA enables early cancer detection with high sensitivity (up to 85 %) and specificity (95 %) and provides valuable insights into disease progression and treatment efficacy. Technological innovations, such as next-generation sequencing (NGS) and artificial intelligence (AI), have enhanced the accuracy of ctDNA analysis. Furthermore, ctDNA facilitates personalized treatment strategies by identifying specific genetic mutations, improving therapeutic outcomes. The growing acceptance of ctDNA-based tests, alongside ongoing research into cost reduction and expanded applications, underscores its potential to revolutionize cancer care. This report highlights current trends, recent research, and future directions for integrating ctDNA into routine clinical practice.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100705"},"PeriodicalIF":0.0,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143145769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Extended total semiconservative parotidectomy with skull base resection","authors":"Bipin Thomas Varghese","doi":"10.1016/j.oor.2024.100701","DOIUrl":"10.1016/j.oor.2024.100701","url":null,"abstract":"<div><div>A case of extensive intermediate grade muco epidermoid carcinoma (MEC) of parotid gland which was optimally excised in toto, by a skull base approach in presented. A semiconservative subradical surgery combined with planned post operative radiotherapy was selected to minimise the morbidity.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100701"},"PeriodicalIF":0.0,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143145766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}